← Leaderboards
Mark R Burge
University Of New Mexico
$7,348,770
Attributed
$8,193,926
Total exposure
33
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $813.1K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,418,926 · 34
By mechanism
M01$4,656,344 · 28
R44$1,479,245 · 1
R01$1,367,390 · 1
P20$450,000 · 2
K23$254,880 · 1
R43$211,067 · 1
Top collaborators
- Peter N Soliz3 shared
Most similar at University Of New Mexico
Same institution · by research overlap
- David S Schade$14,177,133
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectInsulinNoninsulin Dependent Diabetes MellitusHuman Therapy EvaluationHypoglycemiaDrug Screening /EvaluationHuman Old Age (65+)Diabetes Mellitus TherapyResearch PersonnelClinical TrialsEthanolFundingSourceResourcesUnited States National Institutes Of HealthBlood GlucoseGrantInstitutionNutrition Related TagComputer Retrieval Of Information On Scientific Projects DatabaseDosage FormsRecoveryDrug Administration Routes
Grant awards (66)
Quantitative Biomarkers of T1D Peripheral Neuropathy using Functional Imaging$684,557
R44 · FY2017 · DK
Quantitative Biomarkers of T1D Peripheral Neuropathy using Functional Imaging$794,688
R44 · FY2016 · DK
Quantitative biomarkers of T1D peripheral neuropathy using functional imaging$211,067
R43 · FY2015 · DK
THE EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES$21,921
M01 · FY2010 · RR · contact PI
EXPLORATION OF THE WEIGHT NEUTRAL EFFECTS OF INSULIN DETEMIR COMPARED TO INSULIN$15,293
M01 · FY2010 · RR · contact PI
REPOSITORY: GCRC RECRUITMENT DATABASE$76
M01 · FY2010 · RR · contact PI
THE EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TPE 2 DIABETES$45,418
M01 · FY2009 · RR · contact PI
EXPLORATION OF THE WEIGHT NEUTRAL EFFECTS OF INSULIN DETEMIR COMPARED TO INSULIN$35,783
M01 · FY2009 · RR · contact PI
REPOSITORY: GCRC RECRUITMENT DATABASE$2,581
M01 · FY2009 · RR · contact PI
Ethanol on Overnight Glucose Regulation in Diabetes$262,040
R01 · FY2008 · DK · contact PI
THE EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES$40,219
M01 · FY2008 · RR · contact PI
EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES MELLITUS$4,845
M01 · FY2008 · RR · contact PI
Ethanol on Overnight Glucose Regulation in Diabetes$267,387
R01 · FY2007 · DK · contact PI
THE EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES$44,397
M01 · FY2007 · RR · contact PI
EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES MELLITUS$21,030
M01 · FY2007 · RR · contact PI
A COMPARISON OF DAILY VS TWICE-DAILY INSULIN GLARGINE$5,608
M01 · FY2007 · RR · contact PI
Ethanol on Overnight Glucose Regulation in Diabetes$275,373
R01 · FY2006 · DK · contact PI
Clinical and Translational Science Center at the University of New Mexico$225,000
P20 · FY2006 · RR · contact PI
CLINICAL AND TRANSLATIONAL SCIENCE CENTER AT THE UNIVERSITY OF NEW MEXICO$225,000
P20 · FY2006 · RR · contact PI
EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES MELLITUS$68,194
M01 · FY2006 · RR · contact PI
A COMPARISON OF DAILY VS TWICE-DAILY INSULIN GLARGINE$16,701
M01 · FY2006 · RR · contact PI
THE EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES$2,783
M01 · FY2006 · RR · contact PI
Ethanol on Overnight Glucose Regulation in Diabetes$282,000
R01 · FY2005 · DK
EFFECT OF ETHANOL ON OVERNIGHT GLUCOSE REGULATION IN TYPE 2 DIABETES MELLITUS$16,145
M01 · FY2005 · RR
EFFECTS OF ORAL ETHANOL ON PITUITARY SENSITIVITY TO GHRH STIMULATION$1,114
M01 · FY2005 · RR
Ethanol on Overnight Glucose Regulation in Diabetes$280,590
R01 · FY2004 · DK
Oral Ethanol on Pituitary Sensitivity to GHRH Stim.$101,117
M01 · FY2004 · RR
A Comparison of Daily vs. Twice-Daily Insulin Glargine$59,217
M01 · FY2004 · RR
The Role of Deficient Nitric Oxide Generation$20,112
M01 · FY2004 · RR
Physiological Response to Hypoglycemia in Non-Insulin Dependent Diabetes$558
M01 · FY2004 · RR
USE OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN A THYROID CANCER PT$282,412
M01 · FY2002 · RR
OPTIMIZATION OF LYSPRO INSULIN IN ANALOG IN TYPE I DIABETES$282,412
M01 · FY2002 · RR
PHYSIOLOGICAL RESPONSE TO HYPOGLYCEMIA IN NONINSULIN DEPENDENT DIABETES$282,412
M01 · FY2002 · RR
TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS$282,412
M01 · FY2002 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN IDDM$282,412
M01 · FY2002 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN NIDDM$282,412
M01 · FY2002 · RR
EFFECTS OF GLYCEMIA ON SMALL BOWEL FUNCTION IN ELDERLY SUBJECTS W/ DIABETES$282,412
M01 · FY2002 · RR
INCIDENCE OF HYPOGLYCEMIA IN ELDERLY TYPE II DIABETICS$0
M01 · FY2002 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN NIDDM$282,412
M01 · FY2001 · RR
TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS$282,412
M01 · FY2001 · RR
PHYSIOLOGICAL RESPONSE TO HYPOGLYCEMIA IN NONINSULIN DEPENDENT DIABETES$282,412
M01 · FY2001 · RR
OPTIMIZATION OF LYSPRO INSULIN IN ANALOG IN TYPE I DIABETES$282,412
M01 · FY2001 · RR
EFFECTS OF GLYCEMIA ON SMALL BOWEL FUNCTION IN ELDERLY SUBJECTS W/ DIABETES$282,412
M01 · FY2001 · RR
USE OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN A THYROID CANCER PT$282,412
M01 · FY2001 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN IDDM$282,412
M01 · FY2001 · RR
MECHANISMS OF HYPOGLYCEMIC VULNERABILITY DUE TO ETHANOL$127,440
K23 · FY2001 · DK
INCIDENCE OF HYPOGLYCEMIA IN ELDERLY TYPE II DIABETICS$0
M01 · FY2001 · RR
MECHANISMS OF HYPOGLYCEMIC VULNERABILITY DUE TO ETHANOL$127,440
K23 · FY2000 · DK
OPTIMIZATION OF LYSPRO INSULIN IN ANALOG IN TYPE I DIABETES$22,433
M01 · FY2000 · RR
EFFECTS OF GLYCEMIA ON SMALL BOWEL FUNCTION IN ELDERLY SUBJECTS W/ DIABETES$22,433
M01 · FY2000 · RR
PREVENTION OF HYPOGLYCEMIA IN ELDERLY SUBJECTS W/ TYPE II DIABETES$22,433
M01 · FY2000 · RR
USE OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN A THYROID CANCER PT$22,433
M01 · FY2000 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN NIDDM$22,433
M01 · FY2000 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN IDDM$22,433
M01 · FY2000 · RR
TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS$22,433
M01 · FY2000 · RR
PHYSIOLOGICAL RESPONSE TO HYPOGLYCEMIA IN NONINSULIN DEPENDENT DIABETES$22,433
M01 · FY2000 · RR
INCIDENCE OF HYPOGLYCEMIA IN ELDERLY TYPE II DIABETICS$0
M01 · FY2000 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN NIDDM$0
M01 · FY2000 · RR
INHALED HUMAN INSULIN VS USUAL SUBCUTANEOUS HUMAN INSULIN THERAPY IN IDDM$0
M01 · FY2000 · RR
INCIDENCE OF HYPOGLYCEMIA IN ELDERLY TYPE II DIABETICS$0
M01 · FY2000 · RR
PHYSIOLOGICAL RESPONSE TO HYPOGLYCEMIA IN NONINSULIN DEPENDENT DIABETES$0
M01 · FY2000 · RR
EFFECTS OF GLYCEMIA ON SMALL BOWEL FUNCTION IN ELDERLY SUBJECTS W/ DIABETES$0
M01 · FY2000 · RR
PREVENTION OF HYPOGLYCEMIA IN ELDERLY SUBJECTS W/ TYPE II DIABETES$0
M01 · FY2000 · RR
TRIAL OF OCTREOTIDE IN HOSPITALIZED PATIENTS$0
M01 · FY2000 · RR
OPTIMIZATION OF LYSPRO INSULIN IN ANALOG IN TYPE I DIABETES$0
M01 · FY2000 · RR
USE OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN A THYROID CANCER PT$0
M01 · FY2000 · RR